Cerevance Announces Presentation at the 34th International Symposium on ALS/MND
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing novel precision therapeutics for central nervous system (CNS) diseases, today announced a poster presentation at the 34th International Symposium on ALS/MND, taking place in Basel, Switzerland from December 6 – 8, 2023. Presentation details Title: The two-pore potassium channel KCNK13 as a target to modulate neuroinflammation in Amyotrophic Lateral SclerosisOverview: Cerevance's unique NETSseq platform has the r
Source: yahoo.com